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Abstract
Current clinical cardiovascular practice requires a clinician to have a strong foundation in multiple aspects of pharmacology.
Modern cardiovascular regimens are complex, and optimal management, application of evolving guidelines, and adoption of new
therapies build off a more basic understanding of pharmacokinetics and pharmacodynamics. In addition, it is likely time to add a
third pillar into this discussion, the expanding field of pharmacogenomics referring to the genetic influences on drug response. This
field has increasing applications in medicine and clearly holds significant promise for cardiovascular disease management.
Awareness of pharmacogenomic advances and the fundamentals of pharmacokinetics and pharmacodynamics can help the clinician more easily deliver great care. Here we attempt to briefly summarize and simplify key concepts of pharmacokinetics,
pharmacodynamics, and pharmacogenomics relevant to the cardiovascular disease practitioner.
Keywords
cardiovascular pharmacology, cardiovascular pharmacogenetics

Introduction
Cardiovascular disease requires the practicing clinician to
have a strong foundation in multiple aspects of pharmacology
including that of pharmacokinetics, pharmacodynamics, and
pharmacogenomics. Here we attempt to briefly summarize and
simplify some of these key concepts with application to current
clinical cardiovascular disease practice.

Cardiovascular Pharmacokinetics
Understanding the effect a medication may have on the cardiovascular system necessitates an understanding of how the
drug will reach the desired target. The term pharmacokinetics
refers to the action the body takes on a medication; this is
broken down into absorption, distribution, metabolism, and
elimination. Having a framework for interpreting a patient’s
response to a drug is crucial, and understanding the pharmacokinetic parameters that vary between drug, host, and disease
state is important for clinical practice and can help decrease the
likelihood of adverse effects by avoiding drug interactions and
anticipating likely onset and duration of action.

Absorption
Absorption is the movement of a drug from its site of administration into the bloodstream. A medication can be absorbed
from the gastrointestinal (GI) tract, through the oral mucosa

(sublingual nitroglycerine), through the skin (transdermal clonidine), or subcutaneously (enoxaparin). Absorption is not
relevant in the setting of intravenous administration since
drug is administered directly into the bloodstream. Oral medications are generally less expensive, easy to administer, and
are the cornerstone for outpatient management of cardiovascular disease. Bioavailability refers to the fractional amount
of a given dose of a drug that is measured in the blood after
administration. All medications have an inherent bioavailability related to efficiency of absorption. For example, the bioavailability of oral amiodarone is approximately 50% because
half as much drug is available after taken by mouth as compared to intravenous administration.
Drugs can be formulated to modify absorption (eg,
immediate-release forms vs extended-release/sustained-release
formulations), which can greatly impact its duration of effect
and ideal dosing interval. An example is nifedipine, which is
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available as an extended-release and immediate-release formulation, each carrying different clinical implications; the extendedrelease formulation can be given once daily, while the
immediate-release formulation must be administered 3 times
daily and can cause rapid hemodynamic changes and in certain
situations has been associated with increased adverse effects.1
Absorption of a drug is also affected by a variety of factors
extrinsic to the medication itself. Transdermal absorption of a
medication administered through a patch can be altered if the
patch has been cut. Subcutaneous drug absorption is affected
by changes in cutaneous blood flow (eg, high dose of vasopressors causing reduced cutaneous perfusion).2 Within the
GI tract, the presence or absence of food, anatomical abnormalities, and/or coadministration of other medications that may
bind the medication (eg, antacids) can impact absorption rates
as well as the presence of heart failure.3
Bioavailability of oral medications is impacted by numerous
pathways within the digestive system, a key one being drug
transporters within the GI tract. For example, P-glycoprotein
(P-gp), an adenosine triphosphate (ATP)-dependent intestinal
transporter, can efflux a drug back intraluminally within the
intestine and can be inhibited or induced with coadministration
of other medications. Since P-gp affects, and is affected by,
many medications, it is important to note which drugs are
P-gp inhibitors, inducers, and substrates in order to anticipate
these interactions. For example, a clinically relevant P-gp interaction occurs when digoxin and amiodarone are coadministered. P-gp efflux of digoxin into the GI tract is inhibited by
amiodarone, leading to a doubling of the digoxin concentration; thus, the digoxin dose should be decreased by half when
initiating amiodarone. It should also be noted that P-gp induction can also occur, although less commonly. One example of a
drug interaction that occurs due to P-gp induction is the clinically significant interaction between rifampin (P-gp inducer)
and the new oral anticoagulant, dabigatran, whose bioavailability may thus be reduced with coadministration due to the P-gp
on its prodrug dabigatran etexilate.4

Distribution
After a drug is absorbed (reaches systemic circulation), it is distributed within the interstitial and intracellular compartments.
The volume of distribution (Vd) mathematically relates the
total amount of drug administered to the concentration
achieved within the target compartment (usually measure in
blood) and is expressed as a volume (L) or volume/body weight
(L/kg). Understanding a drug’s Vd can be important for estimating the optimal dose of some drugs. Generally, large Vd
reflects the wide distribution of drug, while a small Vd reflects
relative containment in the vascular space.
The Vd can differ from population estimates due to
numerous factors including age, body habitus, disease states,
nutritional status, pregnancy, and critical illness.5,6 For
example, selection of the appropriate bolus dose of lidocaine
is based on Vd and can be affected by these factors with typical loading doses varying between 1 mg/kg and 1.5 mg/kg.
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The 1-mg/kg dose is often used in the elderly patients or in
patients with heart failure since they may have a lower Vd
compared to younger patients or those with normal ventricular function.
A drug exists within the body in either bound or unbound
forms, most often to proteins such as albumin, lipoproteins,
and globulins. This binding may influence Vd because an
increase or decrease in binding of drug to proteins can lead
to a corresponding alteration in the amount of free drug and
on transport across membranes. This concept is important as
drugs are active in their free form (also discussed further
under Pharmacodynamics).

Metabolism
Drug metabolism (also referred to as biotransformation)
occurs primarily through the liver via phase I (oxidation,
hydrolysis, and reduction) and phase II (conjugation) reactions. Phase I reactions include those mediated by the cytochrome P (CYP) 450 enzyme system, estimated to act on
over 90% of all medications. Induction and inhibition of this
critical system helps account for many drug–drug interactions
and also features functional genetic variation, resulting in
clinically significant differences in drug metabolism (discussed later in Pharmacogenomics).
Phase 1 reactions can also include the conversion of a prodrug, a pharmacologically inactive compound, to its active form.
Prodrugs are employed for a variety of reasons such as stability,
absorption, or other particular advantages. For example, enalapril is a prodrug that is rapidly metabolized in the liver into enalaprilat, the active form that inhibits angiotensin-converting
enzyme (ACE). Enalaprilat itself can be administered intravenously, but when using the oral route the prodrug, enalapril maleate is administered. In order to allow for better systemic
absorption and thus serum concentration, the prodrug of enalapril maleate is converted by hydrolysis of an ethyl ester to enalaprilat, which can then inhibit ACE. More often, metabolism
via the CYP system leads to formation of inactive/less active
metabolites; indeed this is part of the pathway of inactivation for
most medications. Another key example of a prodrug is clopidogrel, which has received recent and widespread attention due to
this characteristic and the potential for interactions.7 Clopidogrel
remains inactive until a complex hepatic activation occurs, this
activation utilizes several CYP enzymes that will be discussed
further under Pharmacogenetics as they are implicated in an
individual’s response to the drug.
Changes in the rate of drug metabolism via the CYP enzymatic system are affected by genetics, hepatic function, and
other drugs, which can result in increased or decreased exposure to a medication. The most common CYP enzyme involved
with drug interactions is CYP3A4. Numerous cardiac medications are either inhibitors or substrates of CYP3A4, including
amiodarone, most statins, and several calcium-channel blockers. When a CYP3A4 inhibitor is administered with a CYP3A4
substrate, this could result in increase in medication exposure,
resulting in potential toxicities. Table 1 summarizes important
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Table 1. Selected Substrates and Inhibitors of the CYP450 System.4
Group/Class
Substrates HMG-CoA reductase
inhibitors
b-Blockers
Calcium-channel
blockers
Antithrombotic
Selective aldosterone
receptor antagonists
Proton pump inhibitors
Inhibitors

Calcium-channel
blockers
Antiarthymics
Antilipemics

Medications
Lovastatin,
simvastatin
Metoprolol
Nifedipine and
nisoldipine
Warfarin
Eplerenone
Omeprazole and
lansoprazole
Diltiazem
Verapamil
Amiodarone
Gemfibrozil

Cytochrome
P-450 System
3A4
2D6
3A4
2C9
3A
2C19
3A4
3A4
2C9, 3A, 2D6
2C8

Abbreviation: CYP, cytochrome P; HMG-CoA reductase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

CYP450 enzyme system substrates and inhibitors that the cardiac clinician should recognize.
Drug–drug interaction is a constant consideration for the
practicing clinician; many arise from pharmacokinetic properties and can thus be anticipated and avoided with solid pharmacokinetic knowledge. A recent example is ranolazine and
simvastatin. Ranolazine is a unique antianginal medication,
whose mechanism of action is not completely understood but
is known to be metabolized predominantly by CYP3A and less
so by CYP2D6; it is also a weak inhibitor of CYP3A. Ranolazine has an extensive list of drug interactions including statin
drugs, particularly simvastatin. One pharmacokinetic study of
coadministration of simvastatin and ranolazine showed a
roughly doubling of simvastatin concentration.8 Relevant to
these concerns, the Food and Drug Administration revised dosing recommendations such that if simvastatin is coadministered
with ranolazine, it should be at doses no greater than 20 mg
daily due to concern of myopathy. The evidence for interaction
of statin with ranolazine is most abundant with simvastatin, but
reasonable concern could be extrapolated to other agents in the
class that are cleared by CYP3A. Alternative statins that are not
metabolized significantly by CYP3A such as pravastatin or
rosuvastatin could then be considered in the setting of patients
on ranolazine.
Another drug interaction that has received attention that
involves the CYP enzymatic system is clopidogrel and its
interaction with omeprazole. Clopidogrel is an antiplatelet
drug crucial in multiple areas of cardiovascular medicine and
is also a prodrug processed by the CYP isoenzymes, namely
CYP2C19. Omeprazole, a proton-pump inhibitor (PPI), often
used for patients at high risk or with known upper GI bleeding, is also processed by the CYP2C19 enzyme; when used in
combination, the interaction of omeprazole with CYP2C19
results in inhibition of clopidogrel with proven effect on
platelet activity.9 The clinical importance of the interaction
between clopidogrel and omeprazole remains controversial

but to note this alleged interaction is not a class effect of
PPIs.10

Elimination
Elimination refers to how the medication exits the body. This
could be the drug in its original form or after being converted
to active or inactive metabolites. Elimination is usually either
through renal excretion in urine or the hepatic route into stool.
Renal clearance is a crucial mechanism of drug elimination;
patients with renal dysfunction have reduced clearance of drugs
with renal excretion and are often at greater risk of toxicity
from medications. For example, the patient with atrial fibrillation on rivaroxaban with reduced creatinine clearance (30-49
mL/min) requires a dose adjustment to 15 mg daily from
20 mg, and its use is contraindicated with creatinine clearance
of less than 30 mL/min due to increased bleeding risk.11
Another example is dabigatran, used for the same purpose of
anticoagulation for atrial fibrillation, the dose is 150 mg twice
daily, but with renal impairment (creatinine clearance of 15-30
mL/min), the dose is 75 mg twice daily due to the increased
half-life secondary to the nature of dabigatran’s renal elimination.12 Most renal elimination occurs via glomerular filtration
and secretion into the renal tubules; dysfunction within these
mechanisms, either through drug effect or innate function, can
have consequences for drug exposure. For example, dofetilide,
an antiarrhythmic, undergoes glomerular filtration as well as
secretion in renal tubules. Agents that block tubular secretion
such as hydrochlorothiazide, cimetidine, and ketoconazole can
result in accumulation of dofetilide with potential for toxicity
including QT prolongation and ventricular arrhythmias.
A key pharmacokinetic parameter relevant for the practicing clinician is half-life, which is the amount of time
required for the concentration of drug to be reduced by half.
Steady state is the point at which drug administration is equal
to drug elimination. When discontinuing a medication, it generally takes 4 to 5 half-lives for the drug to be nearly completely removed from the body, conversely when initiating
a drug, 4 to 5 half-lives will also be required to achieve
steady-state concentrations.

Cardiovascular Pharmacodynamics
The term pharmacodynamics refers to the relationship between
the drug concentration at the site of action and the biological
effect. Medications generally interact with a specific target in
the body, this interaction enhances, suppresses, or changes the
function of the target and thus produces an effect. Macromolecules within the body, such as neurohormonal signaling
receptors (eg, adrenergic receptors), enzymes (eg, 3-hydroxy3-methyl-glutaryl-coenzyme A reductase [HMG-CoA-reductase] and vitamin K 2,3-epoxide reductase [VKORC1]), and
ion channels (eg, calcium channels) serve as the target for
many medications. Medication interactions with specific target
receptors may vary across the population, this concept will be
discussed in more detail under Pharmacogenomics.
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Cardiac medications frequently stimulate or block a signaling receptor. For example, the b-adrenergic receptor is
stimulated by dobutamine, thus termed an agonist, while
medications that block the action of b-adrenergic receptor
such as metoprolol are called antagonists. Antagonists can
be further qualified as competitive, taking the place of a naturally occurring ligand (eg, epinephrine) to block activity, or
noncompetitive, which bind elsewhere on the receptor and
thus are less affected by the concentration of the usual ligand.
Another common type of cardiovascular drug is that which
has a pharmacodynamic effect by inhibiting the action of an
ion channel. Calcium-channel blockers inhibit the influx of
calcium into cardiac and other muscle cells, which in the cardiac pacemaker cells reduces chronotropic activity, in other
myocardium can result in reduced inotropy, and in vascular
smooth muscle can lead to vasodilatation. Vaughn-Williams
class III antiarrhythmics inhibit efflux of potassium through
potassium channels. A notable pharmacodynamic effect of
the class III antiarrhythmic drugs is prolongation of the QT
interval. Concomitant use of more than one medication that
prolongs the QT interval could result in a pharmacodynamic
drug interaction, increasing the patient’s risk for developing
Torsades de Pointes.
Enzyme inhibition is another important target of many important cardiovascular medications. The HMG-CoA-reductase inhibitors are a class that produces a pharmacodynamic response
through enzyme inhibition. The HMG-CoA-reductase inhibitors
block the enzyme responsible for the final step of cholesterol formation, leading to the pharmacodynamics effect of reduced
intracellular cholesterol levels in the liver, which then causes
enhanced reuptake of low-density lipoprotein (LDL) particles
from plasma to liver, subsequently lowering plasma LDL levels.
Another example is VKORC1, which is the target of warfarin.
Warfarin inhibits VKORC1 from reducing vitamin K leading
to the pharmacodynamic effect of a decrease in production of
vitamin K-dependent clotting factors.
Targets of drugs may also be specific proteins where the
drug may enhance or impair a protein-dependent physiologic
process. For example, within the coagulation cascade, both
unfractionated heparin and bivalirudin are good examples.
Unfractionated heparin exploits the action of the protein antithrombin through binding and altering the structure slightly,
which subsequently enhances its action of inactivating activated thrombin; thus, unfractionated heparin produces an
antithrombotic effect due to greater inactivation of thrombin.
On the other hand, bivalirudin is a direct thrombin inhibitor,
it binds to thrombin and prevents thrombin from converting
fibrinogen to fibrin, resulting in the antithrombotic effect.
An understanding of pharmacodynamics may be useful in
understanding differences in patient outcomes between medications with a similar mechanism of action. For example, the
adenosine receptor antagonists all inhibit platelet activation
through blockade of the P2Y12 receptor. However, prasugrel
and ticagrelor produce faster and more extensive inhibition
of platelet activation than clopidogrel.13,14 This difference in
pharmacodynamic response could be one potential explanation
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for greater efficacy with both prasugrel and ticagrelor or greater
bleeding risk with prasugrel, as compared to clopidogrel.15,16
As discussed previously, drug interactions can often arise
via pharmacokinetics, but interactions can also occur via pharmacodynamic considerations. Examples include the impaired
response to dobutamine in patients receiving b-blockers mentioned earlier or additive heart rate lowering when nondihydropyridine calcium-channel blockers and b-blockers are
coadministered.
An awareness of the interplay between pharmacokinetics
and pharmacodynamics is important in practice. Aspirin irreversibly inhibits the action of cyclooxygenase (COX) enzyme
in the platelets, leading to prevention of platelet activation.
While the pharmacodynamic effect of most drugs will not be
present 4 to 5 half-lives after discontinuation, the pharmacodynamic effect of aspirin persists long after 4 to 5 half-lives have
passed (approximately 12-24 hours for aspirin). This is because
the irreversible inhibition of the COX enzyme in platelets renders those platelets permanently inactive. Therefore, the antiplatelet effect of aspirin does not normalize until new
functional platelets have been generated, which generally takes
approximately 1 week.

Cardiovascular Pharmacogenetics
There are many factors that contribute to individual variation in
response to medications; the study of relation between genotypic and the phenotypic response to a medication is pharmacogenetics. The terms pharmacogenetics and pharmacogenomics
are often used interchangeably, though pharmacogenomics technically should be used to describe the study of gene-based differences in drug response using a broad or even genome-wide
approach, whereas pharmacogenetics would technically apply
in discussions of specific genes or variants.17 There are numerous barriers to implementing pharmacogenomics into clinical
practice, one of which is the current knowledge base.18 As
discussed in the previous sections on Pharmacokinetics and
dynamics, many nongenetic factors (eg, age, organ function, and
drug interactions) influence medication response; thus, it is
important to view pharmacogenetic factors within this larger
framework, supplementing (not supplanting) other more conventional predictors. Moreover, pharmacogenetic factors generally
operate through and interact with pharmacokinetics and pharmacodynamics; thus our knowledge of these is a necessary basis in
which to incorporate the contribution of genetics.
Previously solely a research field, evidence that genetic
polymorphisms alter the pharmacokinetics, pharmacodynamics, and thus the clinical response to a medication is now
well established.17 Although progress has been slower in cardiovascular disease, pharmacogenetics is being used very
commonly clinically in the field of oncology. However,
examples of clinical use in cardiovascular disease are occurring despite adoption being uneven and slow, and promise
remains as research techniques and our knowledge base continue to expand. Also, real-life clinical challenges exist,
which can be potentially mitigated via personalized medicine,
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thus the potential profit remains high. At this time in cardiovascular disease, an exhaustive knowledge of all previous
associations is not worthwhile, but an understanding of the
general principles and the current (and near future) clinical
applications are warranted, and can help the clinician to avoid
toxicity or treatment failure.
Variation in DNA sequences leading to alterations in phenotype, termed mutations, is rare, occurring generally <1%.
Some of these can lead to clinical and genetic phenotypes
such as hypertrophic cardiomyopathy, familial Wolff-Parkinson–White syndrome, or congenital long QT syndrome; not
all rare variants are disease causing and some more common
variants can be associated with phenotypic changes. More
common variants (roughly 1%) are called polymorphisms,
can come in several subtypes, and are widespread throughout
the genome. There are insertions, deletions, repeats, and
copy-number variants, but the most common type is the
single-nucleotide polymorphism (SNP), essentially a substitution of one nucleic acid for another at a particular locus in the
genome. Single-nucleotide polymorphisms are thought to
have 300 to 1000 nucleotides with estimates totaling up to
30 million, depending on the population.19
Genetic components of drug response were described in
the literature as early as the 1950s; first with the observation
that individuals when given succinylcholine (a suxamethonium derivative) resulted in what we now know as malignant
hyperthermia and led to the discovery of pseudocholinesterase
deficiency.20 Initial applications of pharmacogenetics were
related to altered pharmacokinetics, specifically drug metabolism, and this remains one of the more common areas of application today. Early examples were limited to medications with
very narrow therapeutic indices; a classic example being
azathioprine and the gene thiopurine methyl transferase (TPMT).
Azathioprine is an anticancer and immune-suppressing agent
(can be used in heart transplantation), and TPMT is primarily
involved in the inactivation of 6-mercaptopurine (the active
metabolite of azathioprine) into an inactive by-product. Polymorphisms in the gene TPMT can disable this enzyme, thus
exposing the patient to higher than anticipated levels and causing
toxicity, typically bone marrow suppression. Clinical testing for
genotype allows for identification of patients with those polymorphisms and for whom reduced doses of azathioprine should
be used, avoiding bone marrow toxicity.
Developments within cardiac pharmacogenomics have progressed with discoveries that variants are associated with modified effect or metabolism of many commonly prescribed
cardiovascular medications such as b-blockers, ACE inhibitors, statins, and antiplatelet and anticoagulant drugs.21 The
clinical applications of these discoveries have been slower but
there are a few that, while controversial, could be used today,
particularly clopidogrel, warfarin, and statin pharmacogenetics
(Table 2). Platelet response to clopidogrel is highly heritable
with multiple SNPs implicated affecting pharmacokinetics and
pharmacodynamics.22 As described previously, clopidogrel
ingested in its inactive form and is activated largely by
CYP2C19, after which it blocks the adenosine diphosphate
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Table 2. Summary of Cardiovascular Pharmacogenetics With Known
Clinical Implications.31
Drug
Warfarin

Gene

Variants

CYP2C9 *2,*3
VKORC1 1639G>A
D36Y
Simvastatin SLCO1B1 rs4149056 T>C
Clopidogrel CYP2C19 *2,*3, *4-*8

Clinical Phenotype
Lower dose requirements
Lower dose requirements
Greater dose requirements
Increased risk of myopathy
Higher platelet reactivity,
worse outcomes after
stenting.

Abbreviations: CYP, cytochrome P; VKORC1, vitamin K 2,3-epoxide reductase
1; SLCO1B1, solute carrier organic anion transporter family, member 1B1.

receptor. Genotype at functional SNPs impacting CYP2C19
identifies subgroups of patients at higher risk of ischemic
events after percutaneous intervention (PCI) while on clopidogrel.23,24 As noted, clopidogrel is also subject to efflux via
P-gp; variants in the gene ATP-binding cassette, sub family
B member 1 (ABCB1) which encodes P-gp, lead to altered
expression of P-gp, which impact bioavailability of the drug
and were associated to increased bleeding post PCI.25 As part
of the Escalating Clopidogrel by Involving a Genetic Strategy–
Thrombolysis In Myocardial Infarction 56 (ELEVATE–TIMI
56) trial, they investigated the effect of escalating maintenance
doses of clopidogrel on platelet reactivity (PR) in patients with
coronary artery disease, taking into account the CYP2C19 genotype, numerous observations with clinical implications have
been discovered including variation in PR over time in individuals.26 These findings carry great clinical implications of clopidogrel use, much like TPMT activity measurement prior to
initiating azathioprine, measurement of PR prior to initiating
clopidogrel may be considered.
A patient may thus be genetically ‘‘resistant’’ to clopidogrel.
While it is not in widespread use today, some centers are indeed
genotyping patients planned for long-term clopidogrel. One
study which tested higher dose clopidogrel to resistant genotype patients was not able to show that this intervention overcame the effect.27 However newer, more potent (and more
expensive) antiplatelet agents are now available, presenting
another possible strategy to perform genotype testing and then
assign patients with the resistant genotype to an alternate agent
while keeping patients with the wild-type genotype on clopidogrel. Clopidogrel ‘‘resistance’’ can thus be a result of genetic
variation and also drug interactions; both etiologies result in
platelets maintaining their functional ability which may have
fatal consequences for an individual.
Another cardiac medication that has undergone much
pharmacogenetic investigation is warfarin. Variants in the
gene coding for vitamin K 2,3-epoxide reductase complex
(VKORC1) and a CYP enzyme (CYP2C9) have been convincingly associated with differences in steady state warfarin
dosing, time to therapeutic international normalized ratio
(INR), and time in therapeutic range. It has not been proven
that clinical outcomes are improved with pharmacogenetic
dosing of warfarin with 2 recent trials showing differing
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results.28 One of the main reasons for this discrepancy
appears to be the larger number of African descendent
patients in the American study. Among African Americans,
genotype guidance actually worsened INR control, and it has
subsequently become clear that there are differing prevalence
of some functional variants within VKROC1 and CYP2C9
between European versus African ancestry groups, and these
differences likely contributed to the differing results seen in
the studies. Thus, the totality of available data suggests that for
patients of European ancestry, genotype-guided warfarin dosing
offers some clinical advantage over standard practice, but additional work would be needed to try to extend this to other ancestral groups particularly African Americans.28 Another large
outcome study is ongoing through the same investigators.
Another potential application today is in regard to simvastatin. There is an increased risk of simvastatin-induced muscle
toxicity in patients with variants in solute carrier organic anion
transporter family, member 1B1 (SLCO1B1). Similar to that
mentioned previously, some centers have started performing
this testing routinely to inform the risk of simvastatin (patients
homozygous for the risk variant have a 15%-20% risk of myopathy). On the other hand, with the availability of newer agents
in the class that have less risk, including atorvastatin, which is
now generic, the pragmatic impetus for pharmacogenetic direction of treatment is much less but does highlight the role of
pharmacogenomics. For example, in the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) study, a genome-wide association study on
patients receiving simvastatin 80 mg daily, revealed patients
with variants in SLCO1B1 genotype had an associated increase
in odds of simvastatin-induced myopathy.29 The same findings
in the Statin Response Examined by Genetic Haplotype Markers (STRENGTH) study with atorvastatin, simvastatin, and
pravastatin with effects negligible for atorvastatin and pravastatin and most pronounced among female participants taking
simvastatin.30

Conclusions
Clinical cardiovascular practice needs great attention to medication effects, both desired and dreaded, requiring a clinician
to have a strong foundation of knowledge in multiple aspects
of pharmacology. Here we provided a review of pharmacokinetics, pharmacodynamics, and pharmacogenomics tailored
for the cardiovascular disease practitioner. Continued selfeducation with attention to the evolving research and entity that
is pharmacogenomics is necessary in this ever-changing practice
with a goal of personalized medicine.
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